N-acetylcystein

ApprovedSmall molecule

SSeoul National University Hospital

N-acetylcystein is one of 75 small molecule programs targeting Myocardial Infarction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Renal InsufficiencyActive, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

Renal InsufficiencyApproved

Active, not recruiting

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Ikorel

Merck & Co.

Phase 3

2 2

Lovenox

Sanofi

Phase 3

1 3

Aranesp

Jardiance

2 5

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

1 6

Aggrastat

MMedicure

Phase 3

1 7

Ticlid

Roche

Phase 3

1 8

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 3

2 9

N-acetylcystein

SSeoul National University Hospital

Approved

1 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Trial1 trial

Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01439828·6 enrolled

Renal insufficiency1 trial

NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization

Completed·SSeoul National University Hospital·Phase 4·NCT00356954·250 enrolled

Myocardial Infarction1 trial

Effect of N-acetylcystein in Myocardial Infarction

Unknown status·TTehran University of Medical Sciences·Phase 3·NCT01741207·100 enrolled

Liver1 trial

Use of N-Acetylcysteine During Liver Procurement

Completed·AAzienda Ospedaliera di Padova·Phase 2·NCT01394497·140 enrolled

Addiction1 trial

Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction

Completed·PPsychiatric University Hospital, Zurich·Phase 4·NCT02626494·71 enrolled

1 more indication

Endothelial Function1 trial

Endothelial Function as a Marker for Blood Pressure Control Among Hypertensive Diabetic Patients

Completed·SSoroka University Medical Center·Phase 1·NCT00337038·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for N-acetylcystein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-acetylcystein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-acetylcystein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSeoul National University Hospital

N-acetylcystein

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Trial1 trial

Renal insufficiency1 trial

Myocardial Infarction1 trial

Liver1 trial

Addiction1 trial

Endothelial Function1 trial

References

Drug Info

Quick Facts

Related News